FindTrial
Sign In

Comparison of efficacy of Tacrolimus versus Cyclophosphamide in Idiopathic Membranous Nephropathy

Comparison of efficacy of Tacrolimus versus Cyclophosphamide in Idiopathic Membranous Nephropathy

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2010/091/000231
Enrollment
50
Registered
2010-05-20
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Idiopathic Membranous Nephropathy

Interventions

Intervention1: Tacrolimus + Prednisolone: Tacrolimus-0.1 mg/kg/d
Prednisolone-0.5 mg/kg/d Control Intervention1: Cyclophosphamide + Prednisolone: Cyclophosphamide-2 Mg/Kg Wt/Day
Prednisolone-0.5 mg/kg/day

Sponsors

AIIMS
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Adults (age > 18yrs) 2. Nephrotic range proteinuria (Urine Pr/Cr ratio > 3 g/g) 3. Biopsy proven Primary Membranous Glomerulonephritis (IMN) 4. eGFR > 30 ml/min (MDRD)

Exclusion criteria

Exclusion criteria: 1. Secondary forms of Membranous glomerulonephritis 2. Use of immunosuppressant in past 12 weeks 3. Presence of contraindications to use of immunosuppressants i.e., pregnancy, active infection 4.eGFR< 30 ml/min (MDRD) 5.Inadequate follow-up

Design outcomes

Secondary

MeasureTime frame
Safety in MGNTimepoint: 1 yr—

Primary

MeasureTime frame
1. To study the response of Tacrolimus and Cyclophosphamide in Idiopathic Membranous Nephropathy 2. To compare efficacy of Tacrolimus versus Cyclophosphamide in Idiopathic Membranous NephropathyTimepoint: 1 yr—

Countries

India

Contacts

Public ContactDr PM Dogra
dodgemanu@gmail.com01126594911

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026